Table 2.

Seroprevalence of Poliovirus Types 1 and 3 by Age of Infants at Testing

Poliovirus VaccineSeroprevalence, % (No. Seropositive/Total No.)
14 weeks (n = 250)18 weeks (n = 224)9 months (n = 250)10 months (n = 462)21 months (n = 445)
Poliovirus type 1
 Arm A (2 IPV)94 (117/125)98 (106/108)100 (108/108)100 (104/104)
 Arm B (2 fIPV)96 (120/125)97 (113/116)100 (114/114)100 (111/111)
 Arm C (2 IPV)100 (125/125)100 (122/122)100 (117/117)
 Arm D (1 IPV + 1fIPV)99 (124/125)100 (118/118)100 (113/113)
Poliovirus type 3
 Arm A (2 IPV)88 (110/125)95 (103/108)100 (108/108)100 (104/104)
 Arm B (2 fIPV)86 (108/125)94 (109/116)98 (112/114)99 (110/111)
 Arm C (2 IPV)95 (119/125)100 (122/122)100 (117/117)
 Arm D (1 IPV + 1fIPV)99 (124/125)100 (118/118)100 (113/113)
Poliovirus VaccineSeroprevalence, % (No. Seropositive/Total No.)
14 weeks (n = 250)18 weeks (n = 224)9 months (n = 250)10 months (n = 462)21 months (n = 445)
Poliovirus type 1
 Arm A (2 IPV)94 (117/125)98 (106/108)100 (108/108)100 (104/104)
 Arm B (2 fIPV)96 (120/125)97 (113/116)100 (114/114)100 (111/111)
 Arm C (2 IPV)100 (125/125)100 (122/122)100 (117/117)
 Arm D (1 IPV + 1fIPV)99 (124/125)100 (118/118)100 (113/113)
Poliovirus type 3
 Arm A (2 IPV)88 (110/125)95 (103/108)100 (108/108)100 (104/104)
 Arm B (2 fIPV)86 (108/125)94 (109/116)98 (112/114)99 (110/111)
 Arm C (2 IPV)95 (119/125)100 (122/122)100 (117/117)
 Arm D (1 IPV + 1fIPV)99 (124/125)100 (118/118)100 (113/113)

Abbreviation: fIPV, fractional inactivated poliovirus vaccine.

Table 2.

Seroprevalence of Poliovirus Types 1 and 3 by Age of Infants at Testing

Poliovirus VaccineSeroprevalence, % (No. Seropositive/Total No.)
14 weeks (n = 250)18 weeks (n = 224)9 months (n = 250)10 months (n = 462)21 months (n = 445)
Poliovirus type 1
 Arm A (2 IPV)94 (117/125)98 (106/108)100 (108/108)100 (104/104)
 Arm B (2 fIPV)96 (120/125)97 (113/116)100 (114/114)100 (111/111)
 Arm C (2 IPV)100 (125/125)100 (122/122)100 (117/117)
 Arm D (1 IPV + 1fIPV)99 (124/125)100 (118/118)100 (113/113)
Poliovirus type 3
 Arm A (2 IPV)88 (110/125)95 (103/108)100 (108/108)100 (104/104)
 Arm B (2 fIPV)86 (108/125)94 (109/116)98 (112/114)99 (110/111)
 Arm C (2 IPV)95 (119/125)100 (122/122)100 (117/117)
 Arm D (1 IPV + 1fIPV)99 (124/125)100 (118/118)100 (113/113)
Poliovirus VaccineSeroprevalence, % (No. Seropositive/Total No.)
14 weeks (n = 250)18 weeks (n = 224)9 months (n = 250)10 months (n = 462)21 months (n = 445)
Poliovirus type 1
 Arm A (2 IPV)94 (117/125)98 (106/108)100 (108/108)100 (104/104)
 Arm B (2 fIPV)96 (120/125)97 (113/116)100 (114/114)100 (111/111)
 Arm C (2 IPV)100 (125/125)100 (122/122)100 (117/117)
 Arm D (1 IPV + 1fIPV)99 (124/125)100 (118/118)100 (113/113)
Poliovirus type 3
 Arm A (2 IPV)88 (110/125)95 (103/108)100 (108/108)100 (104/104)
 Arm B (2 fIPV)86 (108/125)94 (109/116)98 (112/114)99 (110/111)
 Arm C (2 IPV)95 (119/125)100 (122/122)100 (117/117)
 Arm D (1 IPV + 1fIPV)99 (124/125)100 (118/118)100 (113/113)

Abbreviation: fIPV, fractional inactivated poliovirus vaccine.

Close
This Feature Is Available To Subscribers Only

Sign In or Create an Account

Close

This PDF is available to Subscribers Only

View Article Abstract & Purchase Options

For full access to this pdf, sign in to an existing account, or purchase an annual subscription.

Close